Cullinan Therapeutics, Inc. (CGEM) · Oct 1, 2026 · Other events

Cullinan starts zipalertinib first-line NDA, but approval still lies ahead

First-line NDA initiated — Completion expected by year-end 2026

Cullinan’s zipalertinib first-line earnings? No—its NDA process has begun under FDA’s RTOR program after positive Phase 3 data, with completion due by year-end.

Cullinan is building a broader T-cell engager pipeline in autoimmune disease and cancer, while partnered zipalertinib remains its most advanced oncology commercialization opportunity; the company’s pipeline currently lists the relapsed-NSCLC application with a February 27, 2027 PDUFA date.

The regulatory path has moved from clinical success toward formal review. Cullinan has begun the first-line NDA submission process for zipalertinib plus chemotherapy under FDA’s Real-Time Oncology Review program, with the complete submission expected by year-end 2026. 〔0〕 RTOR can let FDA begin reviewing key efficacy and safety data earlier, but it does not guarantee approval or change the normal statutory approval standard.

The underlying trial result is supportive, but the filing adds process rather than new clinical proof. The Phase 3 REZILIENT3 trial had already met its primary endpoint, and those results were presented at the 2026 World Conference on Lung Cancer. 〔1〕 The market already knew the study had succeeded; today’s incremental news is that FDA agreed to the RTOR submission route and Cullinan has started the filing process.

Approval opportunityPotential Taiho milestone
Second-line U.S. approval$30 million (Item 8.01)
First-line U.S. approvalUp to $100 million (Item 8.01)

Two regulatory catalysts now sit on the timeline. The monotherapy application for previously treated patients remains under FDA review with a February 27, 2027 PDUFA target date, while the first-line combination application is expected to be completed by year-end 2026. 〔2〕

Bottom line: This advances zipalertinib from strong Phase 3 data into the regulatory queue and modestly improves execution visibility. It matters because first-line approval would expand the drug’s opportunity and unlock a potential $100 million milestone, but the filing is a submission update—not an approval or a new clinical readout.

What to watch next

Completed first-line NDA submission, expected by year-end 2026

Original filing on SEC EDGAR

More Cullinan Therapeutics, Inc. news

Cullinan starts zipalertinib first-line NDA, but approval still lies ahead | CGEM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.